Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study

Lancet. 2000 Jun 24;355(9222):2217-8. doi: 10.1016/s0140-6736(00)02407-7.

Abstract

Discontinuation of primary prophylaxis against toxoplasma encephalitis was studied in 199 HIV-1-infected patients on antiretroviral combination treatment who had experienced a sustained increase in their CD4 count. During a follow-up of 272 person-years, no cases of toxoplasma encephalitis arose.

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / prevention & control*
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Anti-Infective Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Chemoprevention
  • Cohort Studies
  • Confidence Intervals
  • Encephalitis / parasitology*
  • Encephalitis / prevention & control
  • Female
  • Follow-Up Studies
  • HIV Infections* / drug therapy
  • HIV-1*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Switzerland
  • Toxoplasmosis, Cerebral / prevention & control*

Substances

  • Anti-HIV Agents
  • Anti-Infective Agents